Epidemiology, Molecular genotyping and risk factors of HAV infections in the West Bank, Palestine by حياه سميح  احمد قراقع & Hayah Samih Ahmad Qaraqe
1 
 
Deanship of Graduate Studies  
Al-Quds University 
 
 
 
Epidemiology, Molecular genotyping and risk factors of 
HAV infections in the West Bank, Palestine 
 
 
 
 
Hayah Samih Ahmad Qaraqe 
 
 
 
M.Sc. Thesis 
 
 
 
Jerusalem – Palestine 
1439/ 2017 
2 
 
Epidemiology, Molecular genotyping and risk factors of 
HAV infections in the West Bank, Palestine 
 
 
 
 
 
 
Prepared by: 
Hayah Samih Ahmad Qaraqe 
 
 
B. Sc. Medical Technology - Al-Quds University ,Palestine  
 
 
Supervisor: Dr. Rasmi Abu Helu 
 
 
 
 
 
 
A thesis submitted in partial fulfillment of requirement for the 
degree of Master in Medical Laboratory Science / Diagnostic 
Microbiology and Immunology Track/ Faculty of Health 
Professions / AL-Quds University 
 
 
 
 
Jerusalem – Palestine 
1439 / 2017
3 
 
Al-Quds University 
Deanship of graduate studies 
Microbiology and Immunology 
 
 
 
 
 
 
 
Thesis Approval 
Epidemiology, Molecular genotyping and risk factors of HAV infections 
in the West Bank, Palestine 
 
Prepared By: Hayah Samih Ahmad Qaraqe 
Registration Number: 21310227 
Supervisor: Dr. Rasmi Abu Helu. 
 
 
Master thesis Submitted and Accepted, Date: 17 / 12 / 2017 
 
The names and signatures of the examining committee members are as 
follows:  
 
 
1- Head of Committee: Dr. Rasmi Abu Helu Signature:    
2- Internal Examiner: Dr. Sameer A.Barghouthi Signature   
3- External Examiner: Dr. Kamal Dumaidi    Signature   
 
Jerusalem – Palestine  
1439 / 2017
4 
 
 
Dedication 
 
I dedicate this work to my mother and father, 
 
 
to my dear husband Khalid, 
 
 
to my Lovely Kids; Talya and Ali, 
 
 
to my sisters and my brothers, 
 
 
to all teachers, 
 
to my friends. 
 
 
 
 
 
 
 
 
i 
 
 
 
 
 
 
Declaration 
I certify that this thesis submitted for the degree of Master is the result of my 
own research, except where otherwise acknowledged, and that this thesis (or 
any part of the same) has not been submitted for a higher degree to any other 
university or institution.  
 
 
Signature:   
 
Name: Hayah Samih Ahmad  Qaraqe 
 
Date: 17 / 12 /2017 
 
 
 
 
 
ii 
 
Acknowledgment 
First, and most of all, I would like to thank God on what he granted me. I thank him 
for aspiring me to continue through master’s degree in Medical Laboratory Science. 
I would like to thank who facilitated my path and encouraged me to continue 
educational process, despite the difficulties we were going through, he is my Dad. I also 
would like to express my deep and honest esteem to my mother, whom always supported 
me and gave me strength. 
I would like to thank my dear husband (Khalid) for his support and I also would 
like to thank my lovely kids (Talia and Ali) and forgive me on the time that was spent 
away from them. 
I would like to give a special thanks to my supervisor, Dr. Rasmi Abu Helu, for his 
support, directing, suggestions and patience throughout the process of guidance. It was a 
pleasure working with him.  
I would also like to thank Dr. Amer Al-Jawabreh for genuinely caring about my 
research and for all of the clever suggestions. 
I would like to thank Al-Quds University teaching staff, especially Medical 
Laboratory and Biology Departments Staff. 
I would like to thank Graduate study program coordinator; Dr. Sameer Barghouthi 
for helping me. 
I would like to thank Maha Abu Radaha and Palestinian Ministry of health for help 
in sample collection. 
Finally, I would like to thank my friends specially Dina Zighan and everyone who 
helped and supported me to continue this thesis. 
 
 
iii 
 
Abstract: 
Background 
Hepatitis A virus (HAV) is a food and water-borne virus causing clinical (mainly hepatitis) 
and subclinical disease in human. diagnosis and genotyping of HAV infection is helpful for 
proper treatment and epidemiology surveillance. 
The aim of the present study was to determine the molecular genotyping and the risk 
factors of HAV infection in the West Bank, Palestine using serology and Molecular assay. 
Method: 
In this study, 272 HAV suspected cases were analyzed by ELISA for the presence of 
antibodies to HAV. RNA was extracted from 110 HAV IgM positive human sera. Samples 
found positive by RT-PCR using primers targeting the VP1/VP2A junction and VP1/VP3 
capsid region of HAV, were subjected to sequencing and phylogenetic analyses. 
Results 
IgM type antibodies to HAV were detected in 272 patients ;136 sample as the control 
group were negative for HAV IgM, and 136 cases was positive for IgM,75.74% of them 
were student, differed in age groups and was higher in the age group ≤10years. 
Phylogenetic analysis showed that the majority of HAV strains detected in this study 
belong to the ―HAV 1B‖ cluster.  
iv 
 
Conclusions 
The results indicate that molecular studies determining the HAV genotype variation in 
Palestine are timely and warranted. The majority of IgM positive cases in ≤10 year-old 
patients. Sub-genotype IB is the most prevalent genotype in Palestine.  
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Introduction: 
Hepatitis A virus (HAV) genome is a positive single-stranded RNA genome approximately 
7.5 kb long. The HAV genome composed of three regions; 5’ non-translated region (5’ 
UTR), open reading frame (ORF) and 3’ untranslated region (3; UTR) with poly-A tail 
(Hussain et al.,2011).Hepatitis A virus (HAV) is endemic worldwide, and the most 
causative agent of viral hepatitis, with around half of the cases of hepatitis diagnosed 
worldwide. The HAV endemicity level for a population is defined by the results of age-
seroprevalence surveys; a systematic review on the global prevalence of HAV infection 
was recently published by the World Health Organization (WHO,2010). In addition, 
recently it has been reported as one of the most important human food-borne pathogens 
and is the cause of most outbreaks reported in the Western world. More than 1.4 million 
new HAV infections are reported each year. Most of the world’s population is still at 
moderate-to-high risk of hepatitis A virus (HAV) infection. Areas of the world can be 
characterized as having high, intermediate and low endemicity for hepatitis A. In less 
developed countries with very poor sanitary and hygienic conditions, HAV infection is 
highly endemic and most persons become infected in early childhood. Because infection 
occurs at an early age when the disease is often asymptomatic, reported rates of the disease 
in these areas are relatively low and outbreaks are not common. Areas of high endemicity 
include most of Africa, Asia and Central and South America. Conditions which contribute 
to the propagation of the virus among young children in these areas include household 
crowding, poor levels of sanitation and inadequate water supplies (WHO,2010). In 
developing countries and some regions of developed countries, which include Eastern 
Europe, parts of Africa, Asia and America, sanitary and hygienic conditions vary and some 
children avoid infection during early childhood. Peak rates of infection commonly occur in 
later childhood or adolescence. Paradoxically, since HAV transmission occurs in these 
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areas in older age groups, reported rates of hepatitis A can be higher than in less developed 
countries where HAV transmission is more highly endemic. In most developed countries, 
such as North America, Western Europe, Australia and Japan, sanitation and hygienic 
conditions are generally good and infection rates in children are generally low. Peak rates 
of infection and reported disease tend to be among adolescents and young adults. In these 
areas, large community-wide outbreaks with extended person-to-person transmission can 
still contribute significantly to the burden of hepatitis A disease. In addition, occasional 
outbreaks in child care centers or residential institutions and food borne or waterborne 
epidemics can occur. In some countries with very low prevalence (e.g. Northern Europe), 
disease predominates among specific adult risk groups: travelers to countries where 
hepatitis A is endemic; intravenous drug users; and men with a history of homosexual 
behavior. The prevalence of anti-HAV increases gradually with age, primarily reflecting 
declining incidence, changing endemicity and a resultant lower childhood infection rate 
over time(WHO,2010).At the same time, as the countries around the world developed 
economically, the prevalence of HAV infection will probably fall, but paradoxically 
hepatitis A illness will continue considered a public health problem because the severity of 
symptomatic illness with HAV infection are age-related (2–4years) (Victor et al., 
2006).Finally, HAV is endemic in most of the middle east countries with different 
prevalence rate. In Palestine, (1,031) cases was reported in 2014 with an incidence rate 
22.7 per 100,000 of population; 171 cases in West Bank with an incidence rate 6.1 per 
100,000 of population. (MOH,2014). 
In 2015, the reported cases were 1,397 with an incidence rate of 29.8 per 100,000 of 
population; 481 cases were in West Bank with an incidence rate of 16.8 per 100,000 of 
population. (MoH,2015) 
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In 2016, there was a decrease in the number of cases reported, 780 cases of viral hepatitis 
A were reported with an incidence rate of 17.1 per 100,000 populations, of which 313 
cases in West Bank with an incidence rate of 11.7 per 100,000 populations. 
The mortality rate changes according to the age, while severity of the infection is higher in 
adults than children. It is not possible to distinguish HAV strains by serotyping, but seven 
genotypes can be differentiated with molecular methods.(Kokkinos et al., 2010; Dinc et al., 
2012). 
However, the risk factors and the genotypes of the endemic HAV are not investigated yet. 
Therefore, the aims of the present study were to investigate the different genotypes as well 
as the risk factors of HAV infections in the West Bank, Palestine during the period of 
(2014-2016).  
This study will allow the investigation of a molecular epidemiology of HAV from patient 
with acute hepatitis A, will also determine the demographic distribution of HAV, 
optimizing RT-PCR for direct diagnosis and typing of HAV from clinical sample and will 
investigate the most predominant genotype of HAV that circulates in Palestine as well as to 
study molecular characterization. 
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Chapter One: 
____________________________________________________________ 
Literature Review 
 
1.1Virology: 
Hepatitis A virus (HAV) is a Hepatovirus, member of the Picornaviridae family, is a non-
enveloped (naked), linear, positive single stranded RNA virus of an icosahedral symmetry 
measuring 27-32 nm in diameter (Figure1). The infectious particle consists of capsid 
protein and RNA genome and it has lifelong immunity after natural infection because has a 
single antigenic serotype (Anderson et al., 1988). The virus is thermostable and acid-
resistant. Previously, HAV was thought to be an enterovirus; in 1991, it was subclassified 
into its own unique genus hepatovirus. (Franck et al., 1991). Only one human HAV 
serotype has been identified. HAV strains that are isolated from various parts of the world 
constitute a single serotype but variations in the nucleotide sequences are conceivable in 
the genome district. VP1-2A allows the classification of HAV into seven different 
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genotypes (genotypes I, II, III and VII); which are associated with human infections, 
whereas genotypes IV, V and VI cause infections in simians, Subtype IA appears to be 
responsible for the majority of hepatitis A cases worldwide, but subtype IB viruses have 
been found in the Mediterranean region  (Gharbi-Khelifi et al., 2012). 
The human genotypes that have been identified are stable and can be used to trace 
transmission. HAV vaccine prepared from any human HAV genotype will provide 
protection against infection by all strains (Robertson et al., 1992). After oral inoculation, 
HAV is thought to be transported across the intestinal epithelium by a vectorial transport 
process that is poorly understood, and is taken up by hepatocytes. Specific receptors are 
involved remains uncertain, although a novel glycoprotein has been identified as a cellular 
receptor for HAV in one cell line (Shavrina Asher LV et al.,1995). The liver is the only 
target organ of injury; HAV genomic replication occurs exclusively in the cytoplasm of the 
infected hepatocyte by a mechanism involving an RNA-dependent RNA polymerase. From 
the liver, HAV is transported through the biliary tree to the intestine; its resistance to 
inactivation by bile and intestinal proteolytic enzymes allows it to be shed in the feces 
facilitating fecal-oral transmission. (Kaplan G et al.,1996). 
 
Fig. 1. The internal structure of hepatitis A virus showing capsid proteins and envelopes, structural region, 
positive single stranded RNA (open reading frame) and functional region. (Adapted from: Anderson et al., 
1988). 
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1.2Genome composition and Organization: 
Hepatitis A virus (HAV) is known as a positive sense, single-stranded RNA genome with 
approximately 7.5 kb long and has a large open reading frame that divided into three 
functional areas (P1-P3). The P1region encodes capsid polypeptides VP1-VP3 and putative 
VP4. The P2 and P3 areas encode nonstructural proteins which are essential for infection 
and replication (Hussain et al.,2011). In addition, HAV has a 5’nontranslated region that 
comprises approximately 10% of the HAV genome and a 3’ untranslated region with poly-
A tail. After cleavage by proteases, the single polyprotein of HAV yields three major 
protein groups. While P1 encodes capsid proteins VP1- VP3, P2 and P3 encode non-
structural proteins related to viral replication, including proteases and polymerase (Figure 
2). (Hussain et al., 2011). 
HAV genomic heterogeneity has been revealed  based on different genome regions, 
including those encoding for the virion protein VP3 C-terminus, the VP1 N-terminus  and 
the VP1/2A junction (168bp), which is seems to be the most factor utilizer for HAV 
genotypes (Gharbi-Khelifi et al., 2012). 
 
Fig. 2. Genomic structure of hepatitis A virus: HAV genome is divided into a 5’ un-coding region (5’ 
UCR), a giant open reading frame, and un-coding region (3’ UCR). The coding region is subdivided into 
regions P1, P2 and P3. (Adapted from: Hussain et al.,2011) 
Structural proteins are cleaved by viral protease 3C that is encoded by the P3 region and is 
responsible for most cleavages within the polyprotein. Nonstructural proteins are processed 
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in the P2 and P3 regions and are required for RNA synthesis and virion assembly. The P3 
segment contains the 3A, 3B, 3C and 3D proteins. (MinKyung et al.,2002). 
The 5′ NTR which is the conserve region of the viral genome, has a covalently linked 
virus-specific protein (VPg) rather than a cap structure. This region comprises 
approximately of 735 to740 nucleotides in length, uncapped, covalently-linked to the 
genome, contains an internal ribosomal entry site (IRES) and plays an important role in the 
initiation of translation. (Vaughan et al., 2014; Brown, Day, Jansen& Lemon, 1991). The 
3′UTR of 40 to 80 nucleotides, has a poly(A) tract and translation terminator 
sequence(Vaughan et al., 2014; Brown, et al., 1991).The 3′-UTR of 40 to 80 nucleotides, 
has a poly(A) tract and translation terminator sequence (Nainan et al., 2006). 
Numerous regions on the HAV genome have been used for genotyping analysis by 
sequence analysis including, the C terminus of the VP3, N terminus of the VP1, VP1-2A 
junction, VP1-2B region, entire VP1, and the VP3-2B region (Dinc et al., 2012). 
 
1.3 Life cycle and Replication 
HAV is most commonly contracted via feco-oral route. (Hollinger and Emerson, 2007; 
Sherlock et al., 2008; Spradling et al., 2009). After replication in the oropharynx, salivary 
glands and gastrointestinal tract (the primary sites of virus replication), the virus is 
transported to the major site of replication, the liver, where it is subsequently released from 
liver cells into the bile and then excreted in the feces (Cohen et al., 1989; Lees, 2000; 
Cuthbert, 2001; Hollinger and Emerson, 2007). Figure 5 shows the life cycles of HAV. 
8 
 
 
Figure3. Lifecycle of Hepatitis A virus showing fecal-oral route. (Adapted from source: 
http://pathport.vbi.vt.edu/pathinfo/pathogens/HAV.html). 
The highest level of viral particles is detected in the stool during the initial acute 2-weeks 
period followed by the onset of jaundice, and then levels decrease once jaundice is 
apparent (Tassopoulos et al., 1986). Children can shed the virus for long periods up to 10 
weeks after the onset of clinical illness, whereas infants can shed HAV for up to 6 months 
(Robertson et al., 2000; Rosenblum et al., 1991). There is no evidence of chronic shedding 
of HAV in feces; however, recurrent shedding occurs in persons who have relapsing illness 
(Sjogren et al., 1987). Viremia is also found at the same time when HAV particles are 
shedded in fecal during the incubation period (Hollinger and Emerson, 2007). HAV is 
similar to other picornaviruses in its preference to cytoplasmic replication (Collier and 
John, 2006). Clinical symptoms or an immunologic response does not occur during the 
incubation period (Nainan et al., 2006). Though the complete viral life cycle is not fully 
understood, a general overview of the process can be described based on prior studies in 
cultured monkey kidney and human cells (Feigelstock et al., 1998; Kaplan et al., 1996). 
The initial step of infection is when the virus has gained entry into the blood of an 
9 
 
individual. The virus then circulates through the body to the liver. HAV binds via its 
envelope heterodinemic glycoprotein to a cellular receptor (HAVrc1), a mucin-like 
glycoprotein, on hepatocytes (Feigelstock et al., 1998; Kaplan et al., 1996). The binding of 
HAV and HAVcr1 leads to particle conformational changes and uncoating of the virion 
(Silberstein et al., 2003). The virion uncoats and the viral RNA is released into the 
cytoplasm at about 4 h post-infection (Spradling et al., 2009). After releasing into the 
cytoplasm, the uncoated RNA genome is translated through an IRES-dependent 
mechanism requiring cellular initiation factor to function (Borman and Katherine, 1997). 
To replicate its genome, the positive strand RNA of HAV serves as a template for negative 
strand RNA synthesis by the RNA-dependent RNA polymerase 3D. Then, this negative 
strand intermediate acts as a template for the synthesis of several positive strand RNA 
molecules, which can be translated into proteins, replicated, or packaged into new virion 
(Spradling et al., 2009). 
1.4Transmission and molecular epidemiology: 
HAV infection is a widespread infection; it is the cause of approximately one-half of all 
reported cases of viral hepatitis in the United States. In 2009, it was estimated that more 
than 21,000 cases of hepatitis A occurred in the United States, and 1.4 million cases 
occurred worldwide each year (Keefe, 2006). Africa, Latin America, the middle East, and 
parts of Asia are areas of high endemicity where the majority of infections occur in early 
childhood and show high prevalence of anti-HAV up to 90% in adults (Spradling et al., 
2009).  
The variable age distribution among hepatitis A patients in developing and developed 
countries is a consequence of differing standards of hygiene and sanitation.  
In developing countries with poor sanitary conditions and hygienic practices, most children 
(90%) have been infected with the hepatitis A virus before the age of 10 years. Those 
10 
 
infected in childhood do not experience any noticeable symptoms. Epidemics are 
uncommon because older children and adults are generally immune. Symptomatic disease 
rates in these areas are low and outbreaks are rare, countries with transitional economies, 
and regions where sanitary conditions are variable, children often escape infection in early 
childhood and reach adulthood without immunity. Improved economic and sanitary 
conditions may lead to accumulation of adults who have never been infected and who have 
no immunity. This higher susceptibility in older age groups may lead to higher disease 
rates and large outbreaks can occur in these communities, countries with good sanitary and 
hygienic conditions, infection rates are low (WHO,2017). 
The greater part of the world’s population is still at moderate-to-high risk of hepatitis A 
virus (HAV) infection. At the same time, as the countries around the world developed 
economically, the prevalence of HAV infection will probably fall, but paradoxically 
hepatitis A illness will still consider a greater public health problem. This is because the 
likelihood and severity of symptomatic illness with HAV infection are age-related (2-4 
years)(Victor et al., 2006).HAV infection does not lead to chronic or persistent 
hepatitis.(Hirai et al.,  2016; Lima et al., 2014). HAV molecular epidemiology is important 
to understand the strains that circulate in various geographical regions and trace the source 
of contamination in an outbreak situation (Singh et al., 2015). The most reported risk factor 
of HAV infection ingestion of infected food or water or person-to-person contact, low 
educational level, Low income, traveling to endemic areas, hemophiliacs and contaminated 
food and drink usage, crowding and lack of access to safe drinking water and sanitation 
facilities.  Furthermore, homosexuality (men have sex with men) and drug addicts had 
been reported as HAV risk factors (Jacobsen & Koopman, 2005;Munne et al., 2007; Hutin 
et al., 2000; D'Andrea et al., 2015). HAV infection is a worldwide distributed, although its 
endemicity varies significantly at both national, regional and international levels. It is not 
11 
 
possible to distinguish HAV strains by serotyping, but seven genotypes can be 
differentiated with molecular method (Lemon,1997). 
The HAV incidence is thought to be much higher than reported since not all infected 
individuals were seek medical intervention and thus are not reported.  Lower incidence rate 
and fewer HAV cases are found after improvements in sanitation and living conditions, 
predominantly among all populations in developed countries and those with higher socio-
economic status in developing countries (CDC, 1999). 
Based on serological analyses, a given region can be categorized as having high, 
intermediate and low endemicity: in areas with high endemicity, nearly 100% of the 
adolescent and adult population is seropositive, that is with the infection having been 
acquired during childhood. Areas with intermediate endemicity are characterized by a shift 
in the age of seropositive individuals, from children to adolescents and adults. To date, the 
severity of the disease increases progressively with age, whereas infections during 
childhood are often asymptomatic, occurrence during adulthood is symptomatic and 
associated with a mortality rate of up to 2% in industrialized countries among patients >40 
years (Koff, 1998). 
 Based on Molecular epidemiology The worldwide genotype distribution showed genotype 
I and III comprise the vast majority of human strains within the studied population .Sub-
genotype IA comprises the majority of the human strains studied and constitutes major 
virus population in North and South America, China, Japan, Russia and Thailand. The sub-
genotype IB contains strains from Jordan, North Africa, Australia, Europe, Japan and 
South America. Most of the remaining human HAV strains segregate into genotype III that 
is further divided into two sub-genotypes, IIIA, and IIIB . The sub-genotype IIIA have 
been subsequently identified in specimens collected from humans with hepatitis A in India, 
12 
 
The IIIB subgenotype is responsible for cases of HAV infection in Japan and Denmark 
(Cohen, 1987; Jansen, 1990; Robertson, 1992). 
 
 
1.5 Pathogenesis: 
Virus-induced cytopathology may not be responsible for the pathologic changes seen in 
HAV infection as liver disease may result primarily from immune mechanisms. Antigen-
specific T-lymphocytes are responsible for the destruction of infected hepatocytes (Wang 
C-H et al.,1996). 
Cell-mediated immune mechanisms are thought to bring about the necroinflammatory 
lesions of hepatitis A; CD8 T lymphocytes and natural killer cells have been implicated. 
Hepatocyte death may also occur by apoptosis. In the acute phase of hepatitis A, a high 
level of IgM and IgG, the VP1 protein, which is a major HAV capsid polypeptide, has 
been identified; in serum collected during the early and late convalescence period. 
Antibodies to VP3 and VP1 are also present. Circulating anti-HAV may interfere with the 
intrahepatic spread of HAV to contiguous susceptible cells and limit the development of 
secondary viremia. Non-secretory IgG antibody to HAV is present indefinitely in serum 
after infection. This type of antibody seems to be the means by which the lifelong 
immunity is maintained (Wang C-H et al.,1996). Increased levels of interferon have been 
detected in the serum of HAV-infected patients and are presumably responsible for the 
reduction in virus burden seen in patients following the onset of clinical disease and 
symptoms (Hollinger, 1995). 
Patients with acute viral hepatitis A develop features of cholestasis. Confluent hepatic 
necrosis may lead to fulminant hepatitis and death in 30 -60% of cases. Death appears to 
be inevitable when necrosis involves more than 65 - 80% of the total hepatocyte fraction. 
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In patients who survive an episode of acute fulminant hepatic failure, neither functional nor 
pathologic sequelae are common, despite the widespread necrosis. During the recovery 
stage, cell regeneration is prominent. The damaged hepatic tissue is usually restored within 
8 to 12 weeks (Lemon, 1997). 
1.6 Clinical sign and symptom: 
Hepatitis A infection is mainly asymptomatic among children less than 6 years old and 
symptomatic among older children and adults. After an average incubation period of 28 
days (range, 15 to 50 days), most HAV-infected persons developed nonspecific signs and 
symptoms followed by gastrointestinal symptoms. These, include fever, malaise, anorexia, 
nausea, abdominal discomfort, dark urine and jaundice. About 15 to 20% of the patients 
may have prolonged or relapsing disease lasting up to 6 months (Figure 4). HAV infections 
has also been detected as long as 6 to 12 months after infection (Nainan et al., 
2006;Melhem et al., 2015). Exposure of non-immune adolescents and adults may result in 
severe clinical disease like fulminant hepatic failure (Hussain et al., 2011).  
Fulminant hepatitis is a rare complication of hepatitis A. The risk of acute liver failure 
ranges from 0.015 to 0.5%, and the highest rates occur among young children and older 
adults with underlying chronic liver disease (Nainan et al., 2006). 
The fulminant hepatitis A causes necrosis of the liver that followed by destruction of 
hepatic synthetic processes, excretory functions and detoxifying mechanism. These 
complications occur during the first 4-6 weeks of illness which are characterized by rapid 
onset of high fever, marked abdominal pain, vomiting and jaundice followed by 
development of hepatic encephalopathy associated with deep coma and seizures. Mortality 
increased with rising age and survival being rare over the age 45 years. Clinical signs that 
indicating liver failure include a rapid decrease in the size of the liver, prolongation of the 
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prothrombin time and decrease in the aminotransferase level and the bilirubin level and 
continues to rise (Hussain et al., 2011). 
 
 
Fig. 4. The serological course of hepatitis A virus. The virus can be detected in the feces up 
to 2 weeks before the appearance of the jaundice and up to 2 weeks afterwards. (Adapted 
From Lemon, 1997) 
1.7 Mortality rate: 
The vast majority of hepatitis A patients make a full recovery and fatality rate is low. The 
estimated mortality rate is 0.1% for children less than 15 years old, 0.3% for adults ages  
15-39 and 2.1% for adults over 40 years (Hollinger, 1996; Debray, 1997). The acute HAV 
super infections with chronic liver disease is also associated with severity and high 
mortality rate (Keffe, 1995; Vento, 1998). 
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1.8 Treatment: 
Specific treatment is not available for acute hepatitis A virus infection. As in most cases 
the infection is self-limiting and is followed by complete recovery without chronic 
sequelae, and no specific interventions are required. Complete recovery from symptoms 
following infection may be slow and take several weeks or months. Therapy is aimed at 
maintaining comfort and adequate nutritional balance, including replacement of fluids that 
are lost from vomiting and diarrhea (André, 1995). 
1.9 Antigenicity: 
HAV has only one known serotype, different viral strains show similar reactivity to 
monoclonal anti-HAV antibodies. Antigens of the intact virion are conformational and 
different from those of isolated proteins. Antibodies to purified capsid proteins or to 
synthetic peptides have weak or no detectable neutralizing activity is neutralized by both 
anti-HAV IgG and anti-HAV IgM. No serologic or hybridizing cross reactivity between 
HAV and other viral hepatitis agents, including hepatitis E virus (HEV), have been 
observed. The nonstructural proteins of HAV are also immunogenic during natural and 
experimental infections (Hollinger, 1996; Lemon, 1997) 
1.10 Diagnosis: 
Acute hepatitis due to HAV cannot be distinguished from that due to the other hepatitis 
viruses, serologic tests are necessary for a virus-specific diagnosis. 
Diagnosis of hepatitis is made by biochemical assessment of liver function (laboratory 
evaluation of: urine bilirubin and urobilinogen, total and direct serum bilirubin, Alanine 
aminotransferase enzyme (ALT) and/or Aspartate amino transferase enzyme (AST), 
alkaline phosphatase, prothrombin time, total protein, serum albumin, HAV IgG, IgA, 
IgM, complete blood count). The classical routine diagnosis of acute hepatitis A is made 
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by finding anti-HAV IgM in the serum of patients. A second option is the detection of 
virus and/or antigen in the blood and/or the feces. 
HAV antibodies can be detected by using commercially immunoassay kits (Koff, 1998). 
These assays for anti-HAV IgM and total anti-HAV (IgM and IgG) for assessment of HAV 
status are not influenced by the passive administration of IG, because the prophylactic 
doses are below detection level. At the onset of disease, the presence of HAV IgG is 
always accompanied by the presence of IgM. As IgG anti-HAV persists lifelong after acute 
infection, detection of IgG anti-HAV alone indicates past infection. However, 
commercially available assays detect total anti-HAV (both IgG and IgM antibodies). The 
presence of total anti-HAV and the absence of IgM anti-HAV can be used to differentiate 
acute and previous infections (Lemon, 1997). 
For molecular diagnosis Nucleic acid detection techniques are more sensitive than 
immunoassays for viral antigen to detect HAV in samples of different origins (e.g., clinical 
specimens, environmental samples, or food). HAV has been detected with techniques such 
as restriction fragment length polymorphism, single-strand conformational polymorphism, 
Southern blotting, nucleic acid sequencing-based amplification, nucleic acid hybridization, 
and reverse transcription-PCR (RT-PCR) and antigen capture RT-PCR. Amplification of 
viral RNA by RT-PCR is currently the most sensitive and widely used method for 
detection of HAV RNA (Nainan et al., 2006). 
 
1.11 Prevention Methods and control: 
Prevention methods include improvement of personal hygiene and sanitation are critical 
control of measures for HAV. Control of water quality and management of food are also 
important to prevent outbreaks. Prevention of clinical manifestation of Hepatitis A through 
administration of immune globulin is used mainly for close personal contacts of patients 
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with hepatitis A and for those exposed to contaminated food. Active immune-prophylaxis 
with formalin- inactivated hepatitis A vaccine is highly effective in the prevention of 
hepatitis A. The epidemiology of Hepatitis A varies in different part of the world. Hepatitis 
A vaccine is most effective in preventing illness post-exposure if used within 14 days of 
exposure, particularly if used in conjunction with passive immunization with immune 
globulin (IG). It is recommended for certain susceptible contacts following potential 
exposure to HAV. Therefore, vaccination strategies have to be implemented based on the 
prevalence of the HAV endemicity (CDC, 2003) 
 
1.12 Objectives: 
Main Objective: to investigate the HAV molecular epidemiology among acute hepatitis 
patients in comparison with control group in the West Bank, Palestine during the period of 
(2014-2016). 
Specific Objective:  
1. To determine HAV risk factors using molecular assays 
2. To determine the most risk factors of HAV infection 
3. To study the molecular characterization of the HAV isolates in comparison to 
isolates from the neighboring countries and others 
4. Develop recommendation based on this study 
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Chapter Two: 
____________________________________________________________ 
Materials and Methods: 
2.1 Serum collection: 
Study design: cross-section study design 
Study period: January2014- December2016 
Study participants:  a convince 136 IgM HAV cases were obtained during the period of 
2014-2016. These samples were obtained from the Palestinian central public health 
Laboratories in which all the HAV susceptible cases referred.  An equal 136 individuals 
during the same period which showed IgM HAV negative result were selected as a control 
group.  
The age of HAV cases was range from 1 to 40 years. The cases originated from Alkhalil, 
Tubas, Jenin, Salfit, Ramallah, Bethlehem, Jericho, Al-Quds, Qalqelya and Tulkarem. 
A total of 0.5 ml serum sample from each cases were liquated into two sterile Eppendorf 
tubes (one for HAV IgM and the other for HAV RT-PCR) and stored at -20°C till tested. 
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Data collection: 
The general characteristic, demographic data and the clinical history for each participant 
were collected from the patient’s medical files and by using a baseline questionnaire; the 
collected data include age, sex, demographic, educational level of the parents, clinical, 
socioeconomic information, occupation (Appendix A). 
2.2 Serological assays: 
All the serum samples of the cases and the control group were tested for HAV IgM 
antibodies at the central Public health laboratories, Palestinian Ministry of Health using 
commercially IgM capture ELISA (Architect ELISA) with a sensitivity and specificity of 
>99% according to the manufacturer’s instructions.  
2.3 Molecular assays:  
2.3.1 Extraction of viral RNA:  
The HAV viral RNA was extracted from 200μl of serum samples, using 
a QIAamp MiniElute Virus spin kit for the viral RNA extraction (QIAGEN,) according to 
the manufacturer’s instructions. The final volume of the RNA elute was 35μl.  Briefly, 200 
μl serum was added to 25 μl protease k into sterile eppendorff tube. Then 200 μl of AL 
buffer (lysis buffer containing 28 µg/ml of carrier RNA) was added to the mixture. After 
vortex mixing, the mixture was incubated for 15 minutes at 56 
o
C. Then, 250 μl of absolute 
ethanol was added to the mixture and mix well and the lysate was incubated for 5 minutes 
at room temperature (15–25°C).  lysate were transfer into the QIAamp MinElute column 
and centrifuge for 1 minute at 8000rpm. Then the QIAamp MinElute column was washed 
twice using washing solution provided in the extraction kit. Then, 500 µl of ethanol (96–
100%) was added to MinElute column and centrifuge at 8000 rpm for 1 minute. finally 
after removing the ethanol, the RNA was eluted into sterile eppendorff tube with 35 ul of 
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Buffer AVE (is RNase-free water that contains 0.04% sodium azide to prevent microbial 
growth and subsequent contamination with RNases) provided in the kit. The 
extracted RNA was store at -20 
o
C until tested by PCR.  
2.3.2 Reverse transcription-polymerase chain reaction (RT-PCR) for detection of 
HAV genome: 
The HAV RNA of 110 available serum samples from the IgM HAV positive cases was 
amplified using two primers targeting the VP3/VP1 region of the viral genome described 
previously by Lee et al., (2014).  Briefly, the synthesis of the cDNA and the first round 
amplification of the RT-PCR was carried out in 25μl- reaction mixture containing 
4 μl viral RNA extraction, 10 U Reverse transcriptase (AMV), 
10 pmol of each the forward and the reverse primers:  (HAV1; 5' -
GCTCCTCTTTATCATGCTATGGAT-3' and  rHAV2; 5'-
 CAGGAAATGTCTCAGGTACTTTC-3') and 12.5 μl of PCR Reddy master mix (Thermo 
Scientific). The PCR protocol was:  Reaction for reverse transcription was performed for 
40 min at 48°C, followed by denaturation for 4 min at 95°C; 30 cycles of denaturation for 
30 s at 95°C, annealing for 30 s at 55°C, and extension for 30 s at 72°C; and a final 
extension step for 7 min at 72°C.  PCR products (6 ul) were loaded onto a 2% agarose gel, 
electrophoresed, and stained with ethidium bromide for band visualization (expected 
lengths, 244bp) using the Gel Doc System 2000 (Bio-Rad Laboratories-Segarate, Milan, 
Italy).   
 Eighteen of the 68 PCR positive cases were selected for sequence analysis. To be 
representative, the selection of the 18 sequenced cases was based on the two years of the 
study, the different geographical distribution and the months of HAV cases. 
 The PCR amplicon of the 18 PCR positive amplicon was purified and sequence.  
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HAV identity search was conducted using GenBank Basic Local Alignment Search 
Tool (BLAST) http://www.ncbi.nlm.nih.gov/BLAST/Blast.cgi. A multiple   nucleotide   
alignment   of   isolates in this study and other HAV published   sequences   was   produced   
using MEGA6. A phylogenetic tree was inferred by using the Maximum Likelihood 
method based on the Tamura-Nei model (Tamura K. et al.,1993) with 1000 bootstrap 1000 
replicates 
 
2.4 Statistical analysis:  
A database was set up using the EPI INFO software version 7. The participant 
demographic and socioeconomic status including gender, age, educational level, 
occupation, and region were derived from their study questionnaire. For comparison of 
categorical variables between groups were assessed by using the Chi square test and 
fisher’s exact test. The level of significance adopted for all test was (P <0.05). 
2.5 Ethical consideration 
A written informed consent was obtained from each patient or their Family after they had 
been informed about the aim of the study. They were informed that the questionnaire 
would be administered in privacy, the development of a formal questionnaire ensured that 
similar data were collected from all participants and it also ensured objectivity during the 
data collection process. (Appendix A). 
 Information about the study was given by the research from primary health care centers of 
Ministry of Health, and also by central Public health laboratories (Appendix B and C).   
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Chapter Three: 
___________________________________________________________ 
Results: 
3.1 Description of the participants: 
A total, 272 subjects (136 HAV IgM positive cases and 136 HAV IgM negative) were 
participated in this study. Of the HAV cases, 82 (60.29%) were males and 54 (39.71%) 
were females. The general characteristic of the cases and the control group are shown in 
table 1. 
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Table3.1: general characteristic of the cases and the control group participated in the 
study.  
Variables  Participants N (%) 
Gender 
Male  
Female 
HAV cases group                     Control                  
82 (60.29%)                           60 (45.11%) 
54 (39.71%)                          73 (54.89%) 
Age 
≤10 
>10 -≤ 20 
>20 - ≤ 30 
>30 - ≤ 40 
≥ 40 
 
67 (49.28%)                          21 (15.54%) 
52 (38.24%)                          27 (19.98%) 
15 (11.05%)                          48 (35.55%) 
2 (1.48%)                              20 (14.80%) 
0 (0%)                                    19 (14.06%) 
Place of District 
Tulkarem 
Alkhalil 
Qalqilia 
Tubas 
Nablus 
Ramallah 
Ariha 
Bethlehem 
Al-Quds 
Salfit 
 
29(21.32%)                          7 (5.26%) 
56 (41.18%)                          21(15.79%) 
3 (2.21%)                              8 (6.02%) 
2 (1.47%)  3 (2.26%) 
9 (6.62%)                              9 (6.77%) 
6 (4.41%)                              57(42.86%) 
10 (7.35%)                            7 (5.26%) 
17(12.50%)                           11 (8.27%) 
2(1.47%) 0 % 
2(1.47%)                                       0 % 
Marital status   
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N: number of su 
 
The participants (the cases and the control group) were recruited from all the Palestinian 
districts see Figure 5. 
Married 
Single 
Divorced 
7 (5.14%)                                     63(46.3%) 
129 (94.8%)                                  67(49.2%) 
0  1(0.73%) 
  
Level of education  
< Tawjihi 
>Tawjihi 
Income (monthly income in sheikel) 
≤ 1450 
>1450 
 
Occupation 
Student 
Housewife 
Worker 
Clerical worker 
None  
 
 
 
99 (72.79%)                                 49 (36.03%) 
37(27.20%)                                   87 (63.97%) 
  
12 (8.89%)                                     10 ( 7.35%) 
123 (91.11%)                                118 (86.76%) 
 
  
103 (75.74%) 36 (26.67%) 
5 (3.68%) 28 (20.74%) 
9 (6.62%) 34 (25.19%) 
1 (0.74%) 9 (6.67%) 
18 (13.24%) 28 (20.47%) 
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Fig.5: The number of cases and the control group from each district 
3.2 RT-PCR, HAV genotypes and phylogenetic analysis results: 
Of the 110 available serum samples of the HAV IgM cases, 68/110 (62%) yeild positive 
results for HAV RNA by RT-PCR (figure 6). Out of the 68 positive RT-PCR, only 18 
samples were sequenced. All HAV strains were identified as subgenotype IB.  
 
Fig.6. Agarose gel electrophoresis of selected PCR results 
0
10
20
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40
50
60
Districts distribution of the HAV cases and the control 
group in the present study 
HAV cases Control group
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Phylogenetic analysis revealed that the sequences in the present study showed a closed 
homology with each other and form a separate cluster from other sequences retrieved from 
the gene bank Figure (7( 
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Figure.7: Molecular Phylogenetic analysis by Maximum Likelihood method. 
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 The evolutionary history was inferred by using the Maximum Likelihood method based on 
the Tamura-Nei model (Tamura K. et al.,1993). The bootstrap consensus tree inferred from 
1000 replicates (Felsenstein J, 1985). is taken to represent the evolutionary history of the 
taxa analyzed (Felsenstein J, 1985). Branches corresponding to partitions reproduced in 
less than 70% bootstrap replicates are collapsed. The percentage of replicate trees in which 
the associated taxa clustered together in the bootstrap test (1000 replicates) are shown 
above the branches (Felsenstein J, 1985). Initial tree(s) for the heuristic search were 
obtained by applying the Neighbor-Joining method to a matrix of pair wise distances 
estimated using the Maximum Composite Likelihood (MCL) approach. The analysis 
involved 37 nucleotide sequences. All positions containing gaps and missing data were 
eliminated. There were a total of 158 positions in the final dataset. Evolutionary analyses 
were conducted in MEGA6 (Tamura K. et al.,2013) 
 
 
3.3Hepatitis A infections and associated risk factor in comparison with 
the control group: 
The sex (male), occupation (student), educational level (Elementary-Basic) and Low 
income showed a significant difference for HAV infection in comparison to the control 
group (Table2). 
Table 3.2: Risk factors associated with HAV infections 
 
Sex Case Control Total P value 
Male 82 63 
 
145 
 
P=0.014^ S 
Female 54 73 127  
Occupation    P=0.0001*S 
Student 
 
301 63 969  
Housewife 5 22 66  
Worker 9 34 43  
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Sex Case Control Total P value 
Clerical worker 1 9 10  
None 18 28 46  
Level of education    P=0.0001* S 
Elementary-Basic 99 49 148  
Middle 25 40 65  
University-High 12 47 59  
Income(NIS)       P=0.0021^ S 
<= 1450 12 10 22   
1450-3000 90 68 158   
3000-5000 33 50 83   
5000                     0                   8                    8   
*chi-square test; ^ Exact Fisher test; N: Number of subjects; NS: not significant; sig: significant. 
 
3.4 Comparison of sanitation practices, Personal Lifestyle and clinical 
history between HAV cases and the control group: 
 
Drinking treated water, washing hand after defecation and before eating and eating 
unpeeled fruits were find to be associated significantly with HAV infection (P< 0.05). 
Furthermore, traveling abroad, visiting dental clinics and household contact of HBV and/or 
HCV infection were also find to be associated with HAV infection (P<0.05) as show in 
table3 
Table 3.3: clinical and personal hygiene characteristics of272 subjects of the West 
Bank, Palestine. 
Toilette Case Control Total P Value 
In-house 132 136 268 P=0.12^ NS 
In-yard 4 0 4  
Toilette link      P=0.62^NS 
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Toilette Case Control Total P Value 
Septic tank 65 60 125  
Sewage network 71          76 147  
Treat drinking water    P=0.03^ S 
Yes    1 8           8  
No 135 128          263  
Total 136 135          271  
Wash hands     P=0.9^NS  
Yes 129 129          258    
No 4   5           9    
Wash hands after defecation      P=0.0001^ S 
Every time                                  49            108  157  
Sometimes                                  87              28  115  
wash hands before lunch    P=0.0001^S 
Every time                                   23                 76  99  
Sometime                                   113                  60   173  
Eat unpeeled fruits    P=0.0022^S 
Yes 116 94 210  
No 20    42 62  
Travel abroad    P=0.0003^S 
Yes 19   45 64  
No 116    91 207  
Dental procedure        P=0.016^S 
Yes 31   50 81  
No 102    85 187  
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Toilette Case Control Total P Value 
Blood transfusion          P=0.72^NS 
Yes 3    5                8  
No 133   131           264  
HBV/HCV Contacts    P=0.007^NS 
Yes 18    5             23  
No 118   131             249  
^ Exact Fisher test; NS: not significant; sig: significant 
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Chapter Four: 
 
Discussion and Conclusions: 
4.1 Discussion: 
Molecular markers have gained relevance as important tools for epidemiologic 
investigation, providing information on patterns of transmission and identifying the source 
in both sporadic and epidemic infections )Nainan et al., 2006(. 
The VP1-2A junction, is the most variable regions of the HAV genome, is generally 
chosen for phylogenetic analysis. In the present study, the VP1-2A junction of HAV was 
amplified and sequenced in order to determine the prevalent genotype in Palestine. The 
phylogenetic analysis with sequences derived from 18 RNA positive isolates revealed that 
all Palestinian HAV isolates were clustered on genotype IB 
In many parts of the world, the anti-HAV seroprevalence rate is decreasing. Several factors 
are contributing to the declining infection rate, including increasing socioeconomic status, 
increasing access to clean water, and (in a few parts of the world) the availability of a 
hepatitis A vaccine that was developed in the 1990s. In some cases, this reduced force of 
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infection has significantly increased the average age at infection. This delay in viral 
exposure has created a large population of susceptible adolescents and adults at risk of 
disease and led to outbreaks of hepatitis A. Because the severity of infection increases with 
age, it may be appropriate for Hepatitis A Virus populations with a high proportion of 
susceptible adults to consider implementing vaccination programs targeted to certain 
populations often children. (WHO,2010) 
Hepatitis A is one of the world’s most common viral infections. Although most patients 
recover within two months, most cases of hepatitis A can be transmitted by fecal– oral 
contamination. It has been suggested that this association may largely reflect general living 
conditions and poor sanitation and hygiene, the decrease in number of patients suffering 
acute hepatitis was certainly in relation with the improvement of the socio-economic level 
and the hygiene conditions also Hepatitis A may be acquired from fecaly contaminated 
food or water and from wastewater-contaminated drills or water supplies (Hollinger, 
1996). In our study, the age-distribution showed that HAV infection increased in age ≤10 
.Children under the age of 10 years are particularly effective transmitters of hepatitis A 
infection and are usually asymptomatic. High concentrations of virons are shed in the 
stools of patients during 3 to 10 days prior to the onset of illness till one to two weeks after 
the onset of jaundice. Fecal excretion of HAV persists longer in children and in 
immunocompromised persons and may persist up to 4 - 5 months after infection than in 
otherwise healthy adults (Hollinger, 1996). Thus, young children should be the primary 
focus of vaccination. Also, the risk factors for HAV infection are higher in traveler, most 
travelers have to go through Jordan. It is containing people from all countries and different 
nationalities contained the largest number of refugees because of the political situation. so 
maybe persons who travel to countries are at substantial risk for acquiring hepatitis A, the 
sub-genotype IB detected in Jordan (Taylor,1997). 
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In these study HAV infection was transmitted by dental procedure, little risk exists for 
transmission of HAV and HEV from occupational exposure of dental hygienists to 
patients/clients infected with these viruses (Withers AJ, 1980). 
Important source of infection is eaten raw or inadequately cooked food. Cooked food may 
Become recontaminated after cooking during inappropriate handling in our study unpeeled 
fruit may have been a source of HAV infection. 
Finally, these findings demonstrate that hepatitis A represents a public health problem, 
requiring the investigation of the etiology and rapid action measures to control the 
infection. 
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4.2 Conclusion and Recommendation 
In conclusion, genotype IB was found to be the prevalent genotype in Palestine. Despite 
the low diversity of HAV sequences, application of sequence analysis methodology is also 
important in countries lacking HAV genotype diversity, such as Palestine, to identify HAV 
outbreaks and to provide preventive healthcare measures for those in need, also HAV 
remain an important cause of hepatitis outbreak and is a major public worldwide health 
problem especially in developing countries. It is mostly reported from poor sanitary and 
unhygienic surroundings, which emphasizes the need for improving the public health 
measures to prevent epidemics of hepatitis A. The changes in epidemiological pattern 
would increase the disease burden, may cause large community outbreaks and lead to 
increased healthcare cost. The emergence of new serotype is highly unlikely, although new 
variants can emerge if virus population is forced to severe immune selective pressure. 
Since hepatitis A exists as a single serotype and human is the only host, it is possible to 
eradicate by selective vaccination against individuals who are susceptible and sero-
negative for HAV IgM. 
There is some Limitation in my study, Limited genomic sequencing of cDNA amplified by 
PCR from viral RNA so we need nested PCR to improve sensitivity and specificity and 
Financial aid is limited. 
This is the first study describing the HAV genotypes and strains circulating in Palestine. 
Recommendation of vaccination depends of the HAV endemicity special on children under 
10 years also improvement hygiene, sanitation, living standards, drinking water quality and 
adoption of regulatory measures of food handling would go a long way to interrupt HAV 
transmission 
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Appendix A 
 
HEPATITIS QUESTIONNAIRE 
Patient Name  Date of onset of 
symptoms/sampling 
........./............./................ 
DOB ............../.............../.................... Sex Male                      Female 
Marital status Single                                     Married                       divorce  
Address City/town/camps ................................ District ............................................. 
Level of 
education,  
Elementary school                       Middle school                      University 
Occupation .................................................................................................................................................... 
Income < 14500;            1450-3000,                        3000-5000              >5000NIS 
Clinical history 
Have you ever had surgical procedure?  Yes                                                      No 
If the answer is yes, What type of 
surgical procedure did you do 
 
 
 
......................................................................................................................... 
Do you receive blood transfusion Yes                                                     No 
If the answer is yes, when and where .....................................................................................................................  
Have you ever had a dentist procedures? Yes                                                     No 
Have you ever had jaundice? Yes                                                     No 
Do you have HCV? Yes                                                     No 
Do you have HBV? Yes                                                     No 
Do you have a house hold contact with 
HBV and/or HCV 
Yes                                                     No 
Have you ever been abroad?  Yes                                                     No 
If  yes, where? ..................................................................................................................... 
Personal hygiene: 
Toilette  in house                                                 in yard 
Type flush,                    open pits,                            bucket, ………. 
Linked to septic tank                      sewage system 
Drinking water source Well,           piped into house,           piped into yard,         spring, ...... 
If not pipe lined,  do you treat water before drinking?  Yes    No;        How: 
How often do you wash hands after 
defecation 
Every time                       some times 
How often do you wash hands before 
lunch 
Every time                                      some times 
Eat raw vegetables  Yes                                                     No 
Eat unpeeled fruits Yes                                                     No 
Swimming practice  Yes                                                     No 
Eating out side home Yes                                                     No 
If yes, where  
Do you raise domestic animals?  Yes                                                     No 
 Yes, mention………. 
 No, have animals in vicinity                    Yes                          No 
Lab test results 
HAV IgM Positive                                         Negative 
HBS Ag Positive                                         Negative 
RT-PCR/stool Positive                                         Negative 
HCV Ab Positive                                          Negative 
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لفٍزوس التهبة الكبذ الفٍزوسً البشزي (أ) فً عٍىبت المصل مه التعزف على الىصف الجزٌئً 
 المزضى الفلسطٍىٍٍه الذٌه ٌعبوىن مه أعزاض سزٌزٌة لالتهبة الكبذ الفٍزوسً
 قزاقع أحمذ : حٍبي سمٍح إعذاد
 رسمً أبى حلى د.المشزف : 
 
 الملخص
  ٚؽ١ذ ٚاٌؾّغ إٌٛٚٞٚ٘ٛ ف١زٚص  eadirivanrociP عبئٍخ ِٓ٘ٛ عؼٛ   Aف١زٚص اٌزٙبة اٌىجذ
 .ٔبِٔٛ١زز) 26-72ٌٗ ل١بسٗ ( ANR
ٌٚٙب ِٕبعخ ِذٜ  ANRرزىْٛ ِٓ اٌجزٚر١ٓ ٚؽّغ ٔٛٚٞ ِٓ ٔٛع  ٌٙذ اٌف١زٚص اٌغس١ّبد اٌّعذ٠خ
اٌؾ١بح ثعذ اٌعذٜٚ اٌـج١ع١خ لأْ ٌذ٠ٗ إٌّؾ اٌّظٍٟ اٌّسزؼذ ٚاؽذ ٌٚىٓ الاخزلافبد فٟ رسٍسً 
إٌٝ سجعخ أّٔبؽ  VAH٠سّؼ رظٕ١ف  A2-1PV إٌ١ٛوٍ١ٛر١ذاد ٠ّىٓ رظٛر٘ب فٟ ِٕـمخ اٌغ١َٕٛ
جت ف١ٙب ٘ذٖ الأّٔبؽ اٌغ١ٕ١خ ٚاٌزٟ رزس .)ٚراص١خ ِخزٍفخ (الأّٔبؽ اٌغ١ٕ١خ الأٚي ٚاٌضبٟٔ ٚاٌضبٌش ٚاٌسبثع
اٌّزرجـخ ثبٌعذٜٚ اٌجشز٠خ، فٟ ؽ١ٓ أْ الأّٔبؽ اٌغ١ٕ١خ اٌزاثعخ ٚاٌخبِسخ ٚاٌسبدسخ رسجت الاٌزٙبثبد 
ِسؤٚي عٓ غبٌج١خ ؽبلاد اٌزٙبة اٌىجذ اٌٛثبئٟ أ فٟ عّ١ع  ؽ١ش اْ إٌٛع اٌغ١ٕٟ الاٚي، اٌمزٚدفٟ 
  بٌُ)أٔؾبء اٌع
ٌشزاة اٌٍّٛس ثجزاس شخض ِظبة، ٌٚذٌه ٠ّىٓ أْ رؾذس ٠ٕزمً اٌف١زٚص عجز اٌـعبَ أٚ ا
اٌعذٜٚ ثعذح ؿزق: رٕبٚي ؿعبَ لبَ ثزؾؼ١زٖ شخض ِظبة ثبٌزٙبة اٌىجذ (أ)دْٚ أْ ٠غسً ٠ذ٠ٗ ثعذ 
اٌخزٚط ِٓ اٌّزؽبع، رٕبٚي فٛاوٗ أٚ خؼبر ٍِٛصخ ثفؼلاد شخض ِظبة، شزة ِ١بٖ ٍِٛصخ 
ْ غسً اٌ١ذ٠ٓ ع١ًذا ثعذ اٌخزٚط، عذَ ثبٌف١زٚص، اسزخذاَ ِزؽبع ِشززن ِع شخض ِظبة دٚ
 ثعذ رغ١١ز ؽفبع ؿفً ِظبة ٚاٌعذ٠ذ ِٓ الاسجبة .غسً اٌ١ذ٠ٓ 
أٚ  ٌٍجٍعَٛاٌّجـٓ  اٌـجمخ اٌـلائ١خعجز  اٌف١زٚصثعذ اثزلاع اٌّٛاد اٌٍّٛصخ ثبٌف١زٚص ٠ٕزمً 
ٚرزىبصز داخً ٘ذٖ  خلا٠ب اٌىجذؽ١ش رسزمز فٟ  اٌىجذ، ٚعجزٖ رٕزمً إٌٝ اٌذَٚرعجز ِٓ خلاٌٗ إٌٝ الأِعبء
 .اٌخلا٠ب إٌّبع١خاٌخلا٠ب، ٔز١غخ ٌذٌه رظجؼ ٘ذٖ اٌخلا٠ب عزػخ ٌٙغَٛ 
ٚ٘ىذا ٠ظجؼ اٌّظبة اٌجزاسِٕٚٙب إٌٝ اٌعظبرح اٌظفزاٚ٠خعجز  اٌف١زٚص٠زُ ؿزػ وّ١بد وج١زح ِٓ 
٠ٛ ًِب ٚرسزّز الأعزاع ِٓ أسجٛع إٌٝ  51إٌٝ  19ٔبلًلا ٌٍّزع. رّزذ فزز ؽؼبٔخ اٌّزع ِب ث١ٓ 
 أسجٛع١ٓ.
ٚغبٌجب ِب رّٕؼ الإطبثخ ثبٌزٙبة اٌىجذ اٌٛثبئٟ  ٌٍىجذلا ٠سجت اٌزٙبة اٌىجذ اٌٛثبئٟ أ ػزرًا دائًّب 
 .إٌّبعٟ الاعسبَ اٌّؼبدٖ اٌزٟ رٛفز اٌؾظبٔخ ِٓ اٌّزع لاؽًمب أ ِٕبعخ ِذٜ اٌؾ١بح، ٠ٕزظ اٌغٙبس
ٔٛع اٌغ١ٓ اٌّسؤٚي عٓ أزشبر ٌّعزفخ ٌٍىشف عٓ إٌّؾ اٌٛراصٟ ٚ رُ اعزاء ٘ذا اٌجؾش
ٚ٘ذا ٠ف١ذٔب فٟ اِٛر وض١زح  ٌّٚعزفخ اٌٛطف اٌغش٠ئٟ ثٛسبؿخ عٍُ الأِظبي اٌف١زٚص فٟ فٍسـ١ٓ
ِٕٙب ِعزفخ ٔٛع اٌزـع١ُ إٌّبست لاخذٖ فٟ سٓ اٌـفٌٛٗ ثؾ١ش اْ اغٍج١خ أزشبر ف١زٚص اٌىجذ اٌٛثبئٟ أ 
ٛلارّبَ ٘ذٖ اٌذراسخ رُ ؿك اٌؼفٗ اٌفٍسـ١ٕ١ٙٚأ٠ؼب ٌّعزفخ ِذٜ أزشبرٖ فٟ ِٕبرىْٛ فٟ سٓ ِجىزح 
عّع اٌع١ٕبد ِٓ اشخبص ِظبث١ٓ ثٙذا اٌف١زٚص ٚاشخبص ا٠ؼب سٍ١ّ١ٓ ٌٍّمبرٔٗ ث١ُٕٙ ِٓ عّ١ع 
صُ لّٕب ثزؾٍ١ً اٌع١ٕبد اٌّظبثٗ ؽ١ش لّٕب ثعًّ فؾض  أؾبء ِٕبؿك اٌؼفخ اٌغزث١خ فٟ فٍسـ١ٓ
ؽ١ش  ُِٕٙ ؿلاة %47.57ؽ١ش اْ MgIا٠غبثٟ ٌفؾض 369ِز٠غ وبْ ُِٕٙ  272ي  س١زٌٚٛعٟ
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صُ    RCP noitpircsnart esreveRٕبصُ عٍّسٕٛاد  الً ِٓ عشزاْ اٌفئبد اٌعّز٠ٗ الاعٍٝ وبٔذ 
 . BIاٌغ١ٓ إٌّزشز فٟ فٍسـ١ٓ ٘ٛ ِٓ ٔٛع ؽ١ش ٔزظ اْ   gnicneuqes AND
 
